Stock CTXR CITIUS PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Citius Pharmaceuticals, Inc.

Equities

CTXR

US17322U2078

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-26 pm EDT 		5-day change 1st Jan Change
0.6648 USD -9.25% Intraday chart for Citius Pharmaceuticals, Inc. -11.88% -12.12%
Apr. 26 Citius Pharmaceuticals Launches $15 Million Offering MT
Apr. 11 Citius Pharmaceuticals, Inc. Announces Addition of City of Hope to UMN's Phase 1 Trial of LYMPHIR in Combination with CAR-T for the Treatment of B-Cell Lymphoma CI

Evolution of the average Target Price on Citius Pharmaceuticals, Inc.

Price target over the last 5 years

History of analyst recommendation changes

c77890.JTTxmUQ6KmAjCZylG9Mv3PQGja-ekbQCaTbLcBIf55k.EQeQ4SpyXVF8ROTXdOtosJ10x-uo3Yw1WWyoOnV1oPdQR8X4aXl1UBtI0Q~da877730731e2f636ed8064b582c697c

Analyst Recommendations on Citius Pharmaceuticals, Inc.

HC Wainwright Adjusts Citius Pharmaceuticals Price Target to $4 From $6, Maintains Buy Rating MT
HC Wainwright Adjusts Citius Pharmaceuticals Price Target to $6 From $4, Maintains Buy Rating MT
Maxim Group Initiates Coverage on Citius Pharmaceuticals With Buy Rating, $4 Price Target MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
0.6648 USD
Average target price
4 USD
Spread / Average Target
+501.68%
High Price Target
4 USD
Spread / Highest target
+501.68%
Low Price Target
4 USD
Spread / Lowest Target
+501.68%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Citius Pharmaceuticals, Inc.

HC Wainwright
Maxim

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. CTXR Stock
  4. Consensus Citius Pharmaceuticals, Inc.